Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
IRWD Stock Chart & Stats
$1.63
<$0.01(0.11%)
At close: 4:00 PM EST
$1.63
<$0.01(0.11%)
Day’s Range― - ―
52-Week Range$0.53 - $5.13
Previous CloseN/A
Volume359.32K
Average Volume (3M)1.22M
Market Cap
$269.64M
Enterprise Value$632.64M
Total Cash (Recent Filing)$92.85M
Total Debt (Recent Filing)$598.67M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 06, 2025EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding162,434,130
10 Day Avg. Volume883,204
30 Day Avg. Volume1,218,100
Financial Highlights & Ratios
PEG Ratio-8.00
Price to Book (P/B)-2.34
Price to Sales (P/S)2.01
P/FCF Ratio6.82
Enterprise Value/Market Cap2.35
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda7.91
Forecast
1Y Price Target
$1.00Price Target Upside-38.65% Downside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceManagement expects the rest of the year to show similar strength as 2Q, with guidance for $260-290M total revenue and adjusted EBITDA greater than $105M reiterated.
Revenue GrowthPrescription demand growth continues to be strong with IRWD highlighting 8% y/y volume growth in 1Q25.
Bears Say
Debt And Financial UncertaintyThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Regulatory ChallengesThe FDA requires another confirmatory Phase 3 trial for Apraglutide to validate its efficacy and match previous exposure levels.
Ironwood Pharma News
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $0.53 and its highest was $5.13 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is $269.64M.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Nov 06, 2025 which is in 9 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on Aug 07, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.023 by $0.117.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Overvalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma does not currently pay dividends.
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is 0.09.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 162,434,130 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of $0.14 in its last earnings report, beating expectations of $0.023. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Currently, no hedge funds are holding shares in IRWD
Ironwood Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-38.65% Downside)
$1.00 (-38.65% Downside)
Blogger Sentiment
Bullish
IRWD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 115.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.31%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal (GI) diseases. Headquartered in Cambridge, Massachusetts, Ironwood specializes in creating products aimed at improving patient outcomes in conditions such as irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC). Its flagship product, linaclotide, marketed under the brand name Linzess, is a prescription medication designed to treat these GI disorders, offering relief through a novel mechanism of action.
IRWD Stock 12 Month Forecast
Average Price Target
$1.00
▼(-38.65% Downside)
Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Ownership Overview
13.42% Insiders
14.74% Mutual Funds
0.80% Other Institutional Investors
54.64% Public Companies and
Individual Investors